Methods of making, using and pharmaceutical formulations comprising 7α, 11β-dimethyl-17β-hydroxyestra-4, 14-dien-3-one and 17 esters thereof
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsRichard P. Blye, Hyun K. Kim, Pemmaraju Narasimha Rao, Carmie Kirk Acosta
Life of this patent
Estimating the term…
Abstract
Methods of using 7α,11β-dimethyl-17β-hydroxyestra-4,14-dien-3-one (III) and 17 esters thereof for various hormonal therapies, oral and parenteral dosage forms comprising these actives, and processes for their preparation.
Claims96
A method for providing hormonal therapy to a patient comprising the oral administration of an androgen selected from the group consisting of 7α,11β-dimethyl-17βhydroxyestra-4,14-dien-3-one, 17-ester of 7α,11β-dimethyl-17β-hydroxyestra-4,14-dien-3-one, or mixtures thereof in an amount effective to provide hormonal therapy to a patient in need thereof, wherein the hormonal therapy is selected from the group consisting of hormone replacement therapy in males and females, male contraception, treatment of breast cancer, promotion and maintenance of muscle mass in a patient, treatment of osteoporosis, treatment of anemia, treatment for anabolic support, and hypergonadotropic conditions.
A method for providing hormonal therapy to a patient comprising administering parenterally to the patient an androgen selected from the group consisting of 7α,11β-dimethyl-17β-hydroxyestra-4,14-dien-3-one, a 17-ester of 7α,11β-dimethyl-17β-hydroxyestra-4,14-dien-3-one, and mixtures thereof in an amount effective to provide hormonal therapy to the patient, wherein the hormonal therapy is selected from the group consisting of hormone replacement therapy in males and females, male contraception, treatment of breast cancer, promotion and maintenance of muscle mass in a patient, treatment of osteoporosis, treatment of anemia, treatment for anabolic support, and hypergonadotropic conditions.
Dependencies are inferred from the claim text.